FMA
OCRX

FNY Managed Accounts’s Ocera Therapeutics, Inc. OCRX Stock Holding History

FNY Managed Accounts’s Portfolio OCRX Stock Details OCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,500
Closed -$9.55K – 476
2014
Q4 		$9.55K Buy
+1,500
New +$8.78K 0.01% 178

Other funds holding OCRX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return

FNY Managed Accounts's OCRX Position: Q1 2015 in Review

FNY Managed Accounts sold out of Ocera Therapeutics, Inc. (OCRX) in Q1 2015, closing a stake of 1,500 shares — an estimated $9.55K sold.

FNY Managed Accounts first reported a position in OCRX in Q4 2014 and held it in 1 quarter. The position peaked at $9.55K in Q4 2014. 34 funds tracked by Wall St. Rank hold OCRX as of Q1 2015.

  • FNY Managed Accounts reported no remaining Ocera Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
  • FNY Managed Accounts sold 1,500 Ocera Therapeutics, Inc. shares in Q1 2015, an estimated $9.55K.
  • FNY Managed Accounts first reported a position in Ocera Therapeutics, Inc. in Q4 2014 and held it in 1 quarter.
  • FNY Managed Accounts's Ocera Therapeutics, Inc. position peaked at $9.55K in Q4 2014.
  • 34 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q1 2015.

Based on FNY Managed Accounts's 13F filing for Q1 2015, filed 6 May 2015.